SMRT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SMRT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near short-term resistance, there is no strong proprietary buy signal, and the recent analyst tone has softened from Outperform to Market Perform with a lower price target. While hedge funds have been buying and the options market is heavily skewed toward calls, the absence of recent news or a clear financial growth update makes this a weak long-term entry today. If the investor is impatient and wants an immediate answer, the best call is to hold off rather than buy now.
SMRT is in a modest short-term uptrend in pre-market at 1.32, up 0.76%, but the setup is not strong enough for a confident buy. MACD is positive and expanding, which supports near-term momentum. RSI_6 at 69.63 is near overbought territory, suggesting the move may be stretched. Moving averages are converging, implying a mixed trend rather than a clean breakout. Price is sitting just below/around R1 at 1.326, so it is testing resistance rather than offering a clear discounted entry. The nearby pivot at 1.227 is the key support to watch.
["Hedge funds are buying heavily, with buying up 495.04% over the last quarter.", "Options positioning is strongly bullish, with a very low put-call ratio of 0.07.", "MACD histogram is positive and expanding, supporting short-term momentum.", "Pre-market price is slightly higher, showing some buyer interest.", "Keefe Bruyette still views the company as worth tracking and maintained a positive medium-term growth view in earlier coverage."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Analyst sentiment softened recently: price target was cut to $1.40 from $2 and rating is only Market Perform.", "RSI is near overbought, which reduces attractiveness for an immediate entry.", "Stock is trading right near resistance at 1.326, limiting near-term upside from current levels.", "No recent congress trading data and no notable insider buying signal.", "Historical pattern data suggests weak forward returns over the next day and month."]
No usable latest-quarter financial snapshot was provided because the financial data returned an error. The only financial-related clue is that analysts recently reduced EBITDA estimates after Q4, which implies profitability expectations were pressured. The latest quarter season referenced in the analyst notes is Q4, but no detailed revenue or margin figures are available here, so there is not enough evidence of strong fundamental acceleration for a long-term buy.
Recent analyst trend is mixed to negative. On 2026-05-18, Keefe Bruyette lowered the price target to $1.40 from $2 and kept a Market Perform rating. Earlier in March, the firm had raised the target to $2 and maintained more constructive language, including an Outperform call on one note, but the latest move is clearly more cautious. Wall Street pros: the company’s 2028 targets were described as achievable and visibility improved. Wall Street cons: the lowered target and Market Perform stance suggest limited upside and a more neutral outlook.
